Nevertheless, Zhang et al. pointed out that no differences in the tumorigenic activity were found between CD133- and CD133+ populations from NSCLC patient samples using a more sensitive mouse xenotransplantation assay [97]. This evidence concerns the gene PROM1 and non-small cell lung carcinoma.